Related Experiment Video

Updated: Feb 28, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K

Targeting Stat3 in cancer therapy

Naijie Jing1, David J Tweardy

  • 1Department of Medicine and Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA. njing@bcm.tmc.edu

Anti-Cancer Drugs
|June 3, 2005
PubMed

Insights

Targeting Signal Transducer and Activator of Transcription 3 (Stat3) is crucial for cancer therapy. G-quartet oligodeoxynucleotides (GQ-ODN) offer a promising strategy with effective delivery and specificity for Stat3 inhibition.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Signal Transducer and Activator of Transcription 3 (Stat3) is constitutively activated in numerous human cancers.
  • Activated Stat3 promotes oncogenesis by regulating genes involved in apoptosis, cell cycle progression, and angiogenesis.

Purpose of the Study:

  • To review various therapeutic strategies targeting Stat3 in cancer treatment.
  • To highlight the potential of G-quartet oligodeoxynucleotides (GQ-ODN) as a novel Stat3-targeting therapy.

Main Methods:

  • Review of existing literature on Stat3-targeting cancer therapies.
  • Detailed examination of the G-quartet oligodeoxynucleotides (GQ-ODN) strategy, including its delivery system and specificity.

Main Results:

  • Multiple approaches for targeting Stat3 are under investigation, including antisense strategies, tyrosine kinase inhibitors, and decoy molecules.
  • The GQ-ODN strategy demonstrates effective drug delivery, specific targeting of Stat3 over Stat1, and in vivo efficacy.

Conclusions:

  • Targeting Stat3 represents a viable strategy for cancer therapy.
  • GQ-ODN technology shows significant promise due to its novel delivery system, specificity, and demonstrated in vivo effectiveness.

More Related Videos

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

15.6K
Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome07:23

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome

Published on: June 15, 2016

9.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K